story of the week
[177Lu]Lu-PSMA-617 vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
[177Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (TheraP): A Randomised, Open-Label, Phase 2 Trial
Lancet 2021 Feb 27;397(10276)797-804, MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, DA Pattison, TH Tan, ID Kirkwood, S Ng, RJ Francis, C Gedye, NK Rutherford, A Weickhardt, AM Scott, ST Lee, EM Kwan, AA Azad, S Ramdave, AD Redfern, W Macdonald, A Guminski, E Hsiao, W Chua, P Lin, AY Zhang, MM McJannett, MR Stockler, JA Violet, SG Williams, AJ Martin, ID Davis, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials GroupFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.